← All indications
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
Subtype terms (2)
More specific conditions that are subtypes of Papillomavirus Infections in the MeSH hierarchy.
- Condylomata Acuminata
45 drugs (20 approved, 25 experimental)
- Warts
80 drugs (42 approved, 38 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (8)
Phase 3 trials (21)
- diphtheria, tetanus and whole cell pertussis vaccine
- carrageenan
- fluorouracil
- imiquimod
- Measles, Mumps and Rubella Vaccine, Live
- abiraterone
- hepatitis a vaccine, inactivated
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- attenuated live hepatitis A vaccine
- live tetravalent chimeric dengue vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- as04
- geraniol
- eugenol
- carvone
- nerolidol
- technetium tc-99m pentetate kit
- interferon gamma-1b
- mrna-1273
- 11-valent recombinant human papilloma virus vaccine
- recombinant 14-valent human papillomavirus
Phase 2 trials (43)
- ino-3112
- epetirimod esylate
- aminolevulinic acid
- ap611074
- artemisinin
- cantharidin
- durvalumab
- e7 tcr transduced pbl cells
- paclitaxel
- gsk568893a
- Verpasep
- hydroxyurea
- artesunate
- palbociclib
- alpelisib
- ipilimumab
- carboplatin
- ranpirnase
- bevacizumab
- av2-dm
- tremelimumab
- vgx-3100
- v505
- v504
- docetaxel
- cisplatin
- d-limonene
- viusid
- tea
- infigratinib
- +13 more
Phase 1 trials (10)
Organizations
Organization Involved with Phase 4 Indications (20)
- Merck
- GlaxoSmithKline
- National Cancer Institute (NCI)
- Public Health England
- Murdoch Childrens Research Institute
- Boston University
- Centre Hospitalier Universitaire de la Réunion
- University of Washington
- Johns Hopkins University
- McGill University
- Cayetano Heredia University
- Health Protection Agency, United Kingdom
- University Hospital Virgen de las Nieves
- Free University of Brussels
- University of Wisconsin
- Fundación Vía Libre
- Murdoch University
- National Institute for Public Health and the Environment, RIVM, Holland
- Chinese Academy of Medical Sciences
- Universidad Carlos III Madrid
Organization Involved with Phase 3 Indications (30)
- Novartis
- Shanghai Zerun Biotechnology Co.,Ltd
- The EMMES Corporation
- National Institute of Child Health, Hungary
- AIDS Malignancy Consortium
- Cornell University
- Harvard University
- Hoosier Cancer Research Network
- Kenya Medical Research Institute
- Medical University Innsbruck
- University of Puerto Rico
- University of South Florida
- University of Arkansas
- Laval University
- University of California, Los Angeles
- University of California, San Francisco
- Institute of Hematology and Blood Transfusion, Czech Republic
- University of Kinshasa
- University of the Witwatersrand
- Government of Mexico
- Government of China
- Lee's Pharmaceutical
- University of Sao Paulo
- Charles University
- Bill and Melinda Gates Foundation
- AIDS and Cancer Specimen Resource
- Na Homolce Hospital
- Quebec Public Health National Institute
- University of Antwerp
- Government of Quebec
Organization Involved with Phase 2 Indications (40)
- Eisai
- Takeda
- Anaconda Pharma
- Bavarian Nordic
- Catalysis SL
- Cesa Projects International
- Inovio Pharmaceuticals
- Nventa Biopharmaceuticals Corporation
- Shanghai Zhangjiang Biotechnology Limited Company
- Tamir Biotechnology, Inc.
- Verrica Pharmaceuticals Inc.
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- University of Arizona
- Eastern Cooperative Oncology Group
- Eastern Virginia Medical School
- ECOG-ACRIN Cancer Research Group
- Gynecologic Oncology Group
- Northwell Health
- Northwestern University
- Sanford Health
- University of Iowa
- University of Toronto
- Mayo Clinic
- University of Chicago
- Vanderbilt University
- Shandong University
- Janssen Pharmaceutica NV
- University of Texas at Houston
- Indiana Clinical Trials Center
- University of Alabama, Birmingham
- +10 more
Organization Involved with Phase 1 Indications (13)
- Roche
- Efranat Ltd.
- PDS Biotechnology Corp.
- Shanghai Bovax Biotechnology Co., Ltd.
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- Celerion
- University of Missouri
- Lyndhurst Gynecologic Associates
- Laurel Highlands, OB/GYN, P.C.
- Antiva Biosciences
- 2A Pharma AB
- BlueSky Immunotherapies GmbH
Organization Involved with Other Experimental Indications (7)